Edition:
United States

Cellectar Biosciences Inc (CLRB.OQ)

CLRB.OQ on NASDAQ Stock Exchange Capital Market

1.63USD
26 Jul 2017
Change (% chg)

$0.02 (+1.24%)
Prev Close
$1.61
Open
$1.63
Day's High
$1.64
Day's Low
$1.63
Volume
1,648
Avg. Vol
17,477
52-wk High
$3.46
52-wk Low
$1.13

Latest Key Developments (Source: Significant Developments)

Cellectar Biosciences files for mixed shelf of up to $50 mln
Monday, 5 Jun 2017 05:16pm EDT 

June 5 (Reuters) - Cellectar Biosciences Inc ::Cellectar Biosciences Inc files for mixed shelf of up to $50 million - sec filing.  Full Article

Cellectar Biosciences Q1 loss per share $0.24
Thursday, 11 May 2017 04:05pm EDT 

May 11 (Reuters) - Cellectar Biosciences Inc ::Cellectar Biosciences reports first quarter 2017 financial and corporate performance.Q1 loss per share $0.24.Additional capital will be required for operations beyond Q2 of 2018..  Full Article

Cellectar Biosciences initiates NCI-supported phase ii trial of CLR 131
Thursday, 30 Mar 2017 08:30am EDT 

Cellectar Biosciences Inc : After much anticipation, Cellectar Biosciences initiates NCI-supported phase ii trial of CLR 131 in multiple myeloma and other blood cancers . Cellectar Biosciences-study will be conducted in up to 15 centers in U.S. for patients with variety of orphan-designated relapse or refractory hematologic cancers . Cellectar Biosciences Inc - Cellectar will receive approximately $2 million in a non-dilutive grant to help fund trial from national cancer institute .Cellectar Biosciences Inc - initial efficacy data from study expected as early as second half of 2017.  Full Article

Cellectar Biosciences reports 2016 company performance
Wednesday, 15 Mar 2017 04:15pm EDT 

Cellectar Biosciences Inc :Cellectar Biosciences reports 2016 company performance and continued progress in first quarter 2017.  Full Article

Cellectar Biosciences says cohort 1, cohort 2 patients demonstrated post treatment median survival of 11.9 months, 4.9 months, respectively
Thursday, 1 Dec 2016 08:00am EST 

Cellectar Biosciences Inc : Cellectar Biosciences announces results from the first two cohorts of its CLR 131 phase 1 trial: demonstrates excellent efficacy, overall survival benefit, and progression free survival similar to or better than recently approved therapies . Cellectar Biosciences Inc - cohort 1 and cohort 2 patients have demonstrated post treatment median survival of 11.9 months and 4.9 months, respectively . Cellectar Biosciences - median survival for all evaluable patients in both cohorts continues to increase, to be followed to determine overall survival benefit . Cellectar Biosciences Inc - currently, median overall survival (mos) for each cohort is not yet evaluable . Cellectar Biosciences Inc - company is currently enrolling patients into study's third cohort at a single 25 mci/m(2) dose .Cellectar Biosciences Inc - plans to provide additional data update from study's third cohort at a single 25 mci/m(2) dose, in first half of 2017.  Full Article

Cellectar Biosciences announces recent key accomplishments, Q2 results
Thursday, 11 Aug 2016 04:45pm EDT 

Cellectar Biosciences Inc : Cellectar Biosciences announces recent key accomplishments and second quarter 2016 financial results . Cellectar Biosciences Inc says company expects that additional capital will be required to complete its planned clinical and preclinical development .Cellectar Biosciences Inc says company estimates that its available cash and cash equivalents should fund its planned operations into Q1 of 2017.  Full Article

Cellectar Biosciences files for resale of 300,006 shares
Friday, 17 Jun 2016 04:56pm EDT 

Cellectar Biosciences Inc :Files for resale of 300,006 shares of common stock offered by selling stockholders - SEC filing.  Full Article

Cellectar biosciences says can fund ops into Q1 2017
Thursday, 12 May 2016 04:15pm EDT 

: Cellectar biosciences inc says estimates that its available cash and cash equivalents should fund its planned operations into q1 of 2017 .Cellectar biosciences announces first quarter 2016 financial results.  Full Article

Cellectar Biosciences Inc announces positive data from Phase 1 therapeutic trial of CLR 131 in multiple myeloma
Tuesday, 5 Jan 2016 08:30am EST 

Cellectar Biosciences Inc:Announces positive data from Phase 1 therapeutic trial of CLR 131 in multiple myeloma.Says Phase 1 study demonstrated safety and tolerability with a favorable.  Full Article

Cellectar Biosciences Inc closes on $3.3 million financing
Friday, 2 Oct 2015 08:30am EDT 

Cellectar Biosciences Inc:Says closing of its registered direct offering of 1,017,272 shares of its common stock and Series B pre-funded warrants to purchase 482,728 shares of common stock at a price of $2.20 per share.Says in addition, the company completed the private placement of series A warrants to purchase 1,500,000 shares of common stock at an exercise price of $2.83 per share, which are not exercisable for six months from issuance and are exercisable for five years thereafter.Says gross proceeds from this offering were about $3,300,000, before deducting estimated offering expenses payable by the company.Says Ladenburg Thalmann & Co., Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc, acted as exclusive placement agent for offering.  Full Article

BRIEF-Cellectar Biosciences files for mixed shelf of up to $50 mln

* Cellectar Biosciences Inc files for mixed shelf of up to $50 million - sec filing Source text for Eikon: Further company coverage: